• Gennova from India and the Colombian biotechnology company VaxThera have partnered to make mRNA technology vaccines and other biologicals available to the country.
• This is the beginning of a long-term relationship intended to strengthen Colombia’s fill-and-finish capabilities and complete the transfer of technology necessary to reinforce the country’s local research, development and production of vaccines and biologicals.
• This alliance will strengthen biotechnological capabilities for Colombia and the region.

June 10, 2022. COVID-19 has taught us that the world must be prepared for future pandemics. To protect people from emerging diseases and future pandemics, we must utilize all our human, technological, and logistical capabilities.

VaxThera, a Colombian biotechnology company backed by an investment from Seguros SURA, seeks to contribute to the independence of biologics and health security in Latin America through the research, development, and production of biologics. To achieve this objective, the company has entered a long-term alliance with Gennova Biopharmaceuticals Ltd., a biotechnology company headquartered in Pune, India, that develops, produces and commercializes vaccines and biologicals to treat potentially deadly diseases.

“One of the greatest advances from the pandemic was the use of the mRNA technology to rapidly develop safe and effective vaccines against COVID -19. Through this agreement, Colombia and the region will have access to leading-edge technology to meet this and future outbreaks and pandemics. This is an opportunity to create science and technology in Colombia”, says Jorge Osorio, VaxThera’s CEO.

The alliance between these two companies will make it possible, initially, for VaxThera to commercialize Gennova’s products in the country and the region and to pool efforts to strengthen the experience, update technologies, and manage resources in the country’s scientific fields.

“This agreement is of up-most importance as it will provide the opportunity to offer our vaccines and state-of-the-art biologics to Colombia and other Latin American countries. We know that by walking down this path, hand in hand with VaxThera, we will be able to reach and impact the lives of many people who need products of excellent quality to improve their quality of life”, says Sanjay Singh, Gennova´s CEO.   

This alliance between VaxThera and Gennova is aligned with the government’s goal of creating the capabilities for the future production of vaccines in the country and reaching the independence of biologics and health security in Latin America under high-quality standards and backed by rigorous studies.

About VaxThera
VaxThera is a science-focused Colombian company, dedicated to the research and development of biologicals for the world. The company’s aim is to create sanitary independence based on research, development, and innovation in the areas of biotechnology and health. VaxThera was established through the combination between SURA and globally recognized researchers in biotechnology and human health. The company is led by a team with over 30 years’ experience in biologicals research and development.

About Gennova
Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the research, development, production, and commercialization of biotherapeutics to address life-threatening diseases across various indications. To find out more, visit https://gennova.bio

For more information: 
Eliana Siegert
esiegert@vaxthera.com